Å·ÃËÒÑÅú×¼Äá´ïÄá²¼µÚÈýÏî·ÎÏËά»¯ÊÊÓ¦Ö¢[1]

·¢²¼Ê±¼ä£º2020-07-18 19:54:07 À´Ô´£º
  • ¸ÃÅú¼þÕë¶Ô³ýÌØ·¢ÐÔ·ÎÏËά»¯£¨IPF£©Í⣬¾ßÓнøÐÐÐÔ±íÐÍµÄÆäËûÂýÐÔÏËά»¯ÐÔ¼äÖÊÐԷμ²²¡£¨ILD£©³ÉÈË»¼ÕßµÄÖÎÁÆ¡£[1]
  • ´ËÏî¾ö¶¨ÒÔINBUILD®ÊÔÑéËùÈ¡µÃµÄ½á¹ûΪÒÀ¾Ý£¬ÕâÊÇÊ×ÏîÆÀ¹À¾ßÓи÷ÖÖ¹ãÒåÂýÐÔÏËά»¯ÐÔ¼äÖÊÐԷμ²²¡£¨ILD£©¼°½øÐÐÐÔ¼²²¡ÐÐΪ»¼ÕßµÄÑо¿¡£[2]
  • Äá´ïÄá²¼ÒÑÔÚ80¶à¸ö¹ú¼Ò»ñÅúÓÃÓÚÖÎÁÆÌØ·¢ÐÔ·ÎÏËά»¯£¨IPF£©£¬²¢ÔÚ40¶à¸ö¹ú¼Ò»ñÅúÓÃÓÚÖÎÁÆÏµÍ³ÐÔÓ²»¯²¡Ïà¹Ø¼äÖÊÐԷμ²²¡£¨SSc-ILD£©¡£

µÂ¹úÒó¸ñº²2020Äê7ÔÂ17ÈÕ /ÃÀͨÉç/ -- ²ªÁÖ¸ñÒó¸ñº²¹«Ë¾½ñÌìÐû²¼£¬Å·ÃËÒÑÅú×¼Äá´ïÄá²¼ÖÎÁÆÌØ·¢ÐÔ·ÎÏËά»¯£¨IPF£©Íâ,¾ßÓнøÐÐÐÔ±íÐÍµÄÆäËûÂýÐÔÏËά»¯ÐÔ¼äÖÊÐԷμ²²¡£¨ILD£©»¼ÕßµÄ×·¼ÓÊÊÓ¦Ö¢¡£[1]´ËÏîÅú×¼ÔÚÅ·ÖÞÈËÓÃҩƷίԱ»áÓÚ2020Äê5Ô±íʾ¿Ï¶¨Òâ¼ûÖ®ºó×÷³ö¡£[3]ÃÀ¹úʳƷҩƷ¹ÜÀí¾Ö¡¢¼ÓÄôóÎÀÉú²¿ÒÔ¼°ÈÕ±¾Ò©Æ·¼°Ò½ÁÆÆ÷е¹ÜÀí¾ÖÒÑÓÚ½üÆÚÅú×¼½«Äá´ïÄá²¼×÷ΪÕâÏîÊÊÓ¦Ö¢ÈËȺµÄÊ׿îÖÎÁÆ·½·¨[4,5,6]

¼äÖÊÐԷμ²²¡£¨ILD£©Êǰüº¬200¶àÖֿɵ¼Ö·ÎÏËά»¯µÄ¼²²¡ÈËȺµÄ×ܳơ£·ÎÏËά»¯ÊÇÒ»ÖÖ²»¿ÉÄæµÄ·Î×éÖ¯ñ£ºÛÐγɣ¬»á¶Ô·Î¹¦ÄܲúÉú¸ºÃæÓ°Ïì¡£[7]ÏËά»¯ÐÔILD»¼Õ߿ɷ¢Õ¹Îª½øÐÐÐÔ±íÐÍ£¬´Ó¶øµ¼Ö·ι¦ÄÜϽµ£¬Éú»îÖÊÁ¿½µµÍÓë¹ýÔçËÀÍö£¬ÕâÓëIPF£¨ÌØ·¢ÐÔ¼äÖÊÐÔ·ÎÑ×µÄ×î³£¼ûÐÎʽ£©ÏàËÆ¡£[8]ÎÞÂÛ»ù´¡ILDÕï¶ÏÈçºÎ£¬½øÐÐÐÔÂýÐÔÏËά»¯ÐÔILD¶¼¾ßÓÐÏàËÆµÄ²¡³ÌºÍÖ¢×´¡£¸ß´ï18%-32%µÄ·ÇIPFÐÍ ILD»¼Õß´æÔÚ·¢Õ¹Îª½øÐÐÐÔÏËά»¯¼²²¡µÄ·çÏÕ¡£[9,10]

´ËÏîÅú¼þÒÔINBUILD®ÊÔÑéËùÈ¡µÃµÄ½á¹û×÷ΪÒÀ¾Ý£¬ÕâÊÇÒ»ÏîËæ»ú¡¢Ë«Ã¤¡¢°²Î¿¼Á¶ÔÕÕ¡¢Æ½ÐзÖ×éµÄIIIÆÚÁÙ´²Ñо¿£¬ÆÀ¹ÀÄá´ïÄá²¼¶Ô½øÐÐÐÔÂýÐÔÏËά»¯ILD»¼ÕßµÄÁÆÐ§¡¢°²È«ÐÔºÍÄÍÊÜÐÔ ¡£[2]Ö÷ÒªÖÕµãÊÇ52ÖÜÆÚ¼äÆÀ¹ÀµÄÓÃÁ¦·Î»îÁ¿£¨FVC£©ÄêϽµÂÊ£¨ÒÔºÁÉýΪµ¥Î»£©¡£°²Î¿¼Á×黼Õߵķι¦ÄÜÄêϽµÁ¿Îª188ºÁÉý£¬¶øÄá´ïÄá²¼×黼ÕßΪ81ºÁÉý¡£»ùÓÚ52ÖܵĽá¹û¼ÆËãÄêϽµÂÊ£¬Äá´ïÄ᲼ʹÑо¿ÕûÌåÈËȺµÄ·Î¹¦ÄÜÄêϽµÂÊÏà½ÏÓÚ°²Î¿¼Á¼õ»ºÁË57%¡£[2]ÕâһЧ¹ûÔÚËùÓл¼ÕßÖоù±£³ÖÒ»Ö£¬ÎÞÂ۸߷ֱæÂʼÆËã»ú¶Ï²ãɨÃ裨HRCT£©ÏÔʾºÎÖÖÏËά»¯ÀàÐÍ¡£ÕâÒ²ÓëÄá´ïÄá²¼ÖÎÁÆIPFºÍSSc-ILD»¼ÕßµÄÊÔÑé½á¹û±£³ÖÒ»Ö¡£[2,11,12,13]

ÔÚ±¾ÊÔÑéÖУ¬Ó밲ο¼ÁÏà±È£¬Äá´ïÄá²¼Óë¼±ÐÔ¼ÓÖØ»òËÀÍöµÄ·çÏÕÊýÖµ½µµÍÓйء£[2]ÖÎÁƵÄÒæ´¦¿ÉÄÜ»¹°üÀ¨»¼Õß±¨¸æÖ¢×´£¨ÈçºôÎüÀ§ÄѺͿÈËÔ£©µÄ¶ñ»¯ÓÐËù»º½â¡£[14]´ËÍ⣬ÔÚINBUILD®ÊÔÑéÖй۲쵽µÄ°²È«ÐÔÌØÕ÷Óë´ËǰʹÓÃÄá´ïÄá²¼ÖÎÁÆIPFºÍSSc-ILD»¼ÕßµÄÊÔÑé±£³ÖÒ»Ö¡£[2]

Å·ÖÞÌØ·¢ÐÔ·ÎÏËά»¯¼°Ïà¹Ø¼²²¡ÁªºÏ»á(EU-IPFF)ÃØÊ鳤Liam Galvin˵£º¡°×÷Ϊ¼º±¼ûÇÒΣ¼°ÉúÃü¼²²¡µÄ´ø²¡Éú´æÕߣ¬ÒªÈÃÄúµÄÉùÒô±»Ìýµ½¿ÉÄܷdz£À§ÄÑÉõÖÁÈÃÈ˿ֻţ¬ÓÈÆäÊÇÔÚĿǰûÓÐÖÎÁÆ¿ÉÑ¡µÄÇé¿öÏ¡£¡±¡°Å·Ã˵ľö¶¨¶ÔÓÚÓÉÓÚ½øÐÐÐÔILD¶ø·¢Éú·ÎÏËά»¯·çÏÕµÄ ÈËȺÀ´ËµÊÇÒ»¸öÖØ´óϲѶ¡£·ÎÏËά¿Éµ¼Ö·ι¦ÄܳöÏÖ²»¿ÉÄæµÄ¼õÍË£¬ÉÏÊöÐÂÊÊÓ¦Ö¢µÄ»ñÅú»áΪÏà¹Ø¼²²¡»¼Õß¼°ÆäÇ×È˶¼´øÀ´ºÜ´óµÄÏ£¼½¡£¡±

²ªÁÖ¸ñÒó¸ñº²¸ß¼¶¸±×ܲüæÖÎÁÆÇøÓòÑ×Ö¢¸ºÔðÈËPeter Fang˵£º¡°Å·ÃË×÷³öÅú×¼Äá´ïÄá²¼×÷ΪÊ׸öÊÊÓÃÓÚ¾ßÓнøÐÐÐÔ±íÐ͵ÄÂýÐÔÏËά»¯ÐÔ¼äÖÊÐԷμ²²¡»¼ÕßÁÆ·¨µÄ¾ö¶¨£¬ÎÒÃǶԴ˸е½·Ç³£¸ßÐË¡£¡±¡°ÏËά»¯ÐÔ¼²²¡»á¶Ô»¼ÕßµÄÉú»îÔì³É¾Þ´óµÄÓ°Ïì¡£¸÷ÖÖDZÔÚ¼²²¡¶¼¿Éµ¼Ö·ÎÏËά»¯½øÕ¹£¬¶øµ½Ä¿Ç°ÎªÖ¹»¹Ã»ÓпÉÓõÄÖÎÁÆÑ¡Ôñ¡£ÔÚÖÎÁÆÉÏËùÈ¡µÃµÄÍ»ÆÆÎª»¼Õß´øÀ´ÐµÄÏ£Íû¡£¡±

¹ØÓÚINBUILD®ÁÙ´²ÊÔÑé

INBUILD®ÊÇÒ»ÏîËæ»ú¡¢Ë«Ã¤¡¢°²Î¿¼Á¶ÔÕÕ¡¢Æ½ÐзÖ×éµÄIIIÆÚÁÙ´²Ñо¿£¬ÔÚ15¸ö¹ú¼Ò/µØÇøµÄ153¸öÑо¿ÖÐÐĽøÐУ¬Èë×黼Õß663Ãû¡£ÔÚ52ÖÜÆÚ¼äÄá´ïÄá²¼£¨150 mg£¬Ã¿Ìì2´Î£©¶Ô½øÐÐÐÔÏËά»¯ÐÔ¼äÖÊÐԷμ²²¡£¨PF-ILD£©»¼ÕßµÄÓÐЧÐÔ¡¢°²È«ÐÔºÍÄÍÊÜÐÔ½øÐÐÆÀ¼Û¡£[2]»¼ÕßÈë×éÌõ¼þÒªÇó£ºÄêÁä¡Ý 18ÖÜËꣻ³ö¾ß·ÇÌØ·¢ÐÔ·ÎÏËά»¯µÄ¼äÖÊÐԷμ²²¡Ò½ÉúÕï¶Ï£»¸ß·Ö±æÂʼÆËã»ú¶Ï²ãɨÃ裨HRCT£©ÏÔʾÏËά»¯·Î¼²²¡ÌØÕ÷ÊÜÀÛ°Ù·Ö±È>10%¡£[2]Èë×éÌõ¼þ»¹ÒªÇó»¼ÕßÔÚɸѡǰ24¸öÔÂÄÚ·ûºÏ¼äÖÊÐԷμ²²¡½øÕ¹µÄ±ê×¼£¬Åж¨ÒÀ¾ÝΪÔÚ¸øÓè¼äÖÊÐԷμ²²¡ÁÙ´²³£ÓÃÒ©ÖÎÁÆÇé¿öÏÂÈÔ³öÏÖÓÃÁ¦·Î»îÁ¿Ï½µ¡¢Ó°Ïñѧ¼ì²éÏÔʾÏËά»¯¸Ä±äÔö¼Ó»òÕßÖ¢×´¶ñ»¯¡£[2]

Ñо¿¹²Èë×黼Õß663Ãû£¬ÆäÖÐ412Ãû£¨62%£©¾­¸ß·Ö±æÂʼÆËã»ú¶Ï²ãɨÃ裨HRCT£©ÏÔʾΪÆÕͨÐͼäÖÊÐÔ·ÎÑ×£¨UIP£©±íÏÖģʽ£¬°´1:1±ÈÀýËæ»úÈë×鰲ŎÓÊܿڷþÄá´ïÄá²¼£¨Ã¿ÈÕÁ½´Îÿ´Î150 mg£©»ò°²Î¿¼ÁÖÎÁÆ¡£2Ñо¿µÄÖ÷ÒªÖÕµãΪÓÃÁ¦·Î»îÁ¿ÔÚ52ÖÜÑо¿ÆÚÄÚµÄÄêϽµÂÊÆÀ¹À½á¹û£¨mL/Ä꣩¡£[2]×÷Ϊ·Î¹¦ÄܵÄÒ»Ïî²âÁ¿Ö¸±ê£¬ÓÃÁ¦·Î»îÁ¿£¨FVC£©Ö¸µÄÊÇÔÚ¾¡¿ÉÄÜÉîºôÎüºó¿É´Ó·Î²¿ÓÃÁ¦ÅųöµÄ¿ÕÆøÁ¿¡£Ëæ×ÅÏËά»¯½øÕ¹£¬·Î¹¦ÄÜÖð½¥³öÏÖ²»¿ÉÄæÐÔ¶ñ»¯¡£[2]Ö÷ÒªµÄ´ÎÒªÖÕµãÔòΪµÚ52ÖÜKing¼òÃ÷¼äÖÊÐԷμ²²¡£¨K-BILD£©Îʾí×Ü·ÖÏà½ÏÓÚ»ùÏߵľø¶Ô±ä»¯Á¿£»ÔÚ52ÖÜÑо¿ÆÚÄÚÖÁ¼äÖÊÐԷμ²²¡Ê״μ±ÐÔ¼ÓÖØ»òËÀÍöµÄʱ¼ä£»ÒÔ¼°ÔÚ52ÖÜÑо¿ÆÚÄÚÖÁËÀÍöµÄʱ¼ä¡£[2]¼±ÐÔ¼ÓÖØÖ¸µÄÊǺôÎü¹¦ÄÜÍ»·¢¾ßÁÙ´²ÏÔÖøÐԵĶñ»¯£¬ÔÚÐí¶àÇé¿öÏ·¢²¡Ô­Òò²»Ã÷£¬Æä¿É¶Ô¼²²¡¹ý³ÌÔì³É¸ºÃæÓ°Ïì²¢ÇÒ¾­³£»áµ¼Ö»¼ÕßËÀÍö¡£[2]Ó밲ο¼ÁÏà±È£¬Äá´ïÄá²¼¿ÉÔÚÊýÖµÉϽµµÍ»¼Õß²¡Çé¼±ÐÔ¼ÓÖØ»òËÀÍöµÄ·çÏÕ¡£[2]

¹ØÓÚ½øÐÐÐÔ±íÐ͵ÄÂýÐÔÏËά»¯ÐÔ¼äÖÊÐԷμ²²¡

ÔÚ²»¿¼ÂÇDZÔÚ²¡ÒòµÄÇé¿öÏ£¬¾ßÓнøÐÐÐÔ±íÐ͵ÄÂýÐÔÏËά»¯ÐÔ¼äÖÊÐԷμ²²¡ÔÚ¼²²¡¹ý³Ì¼°Ö¢×´±íÏÖ·½Ãæ¶¼¾ßÓÐÏàËÆÐÔ¡£10¾ßÌå±íÏÖΪ·Î¹¦ÄÜɥʧ¼Ó¿ìÒÔ¼°Éú»îÖÊÁ¿¶ñ»¯£»¸Ã²¡µÄÔ¤ºó½Ï²î¡£[8]

·Î²¿µÄ½øÐÐÐÔÏËά»¯²¡±ä¿Éµ¼Ö·ι¦ÄܳöÏÖ²»¿ÉÄæµÄɥʧ£¬²¢ÇÒÓë¸ß»¼²¡ÂÊ¡¢¸ßËÀÍöÂÊÏà¹ØÁª¡£Æ½¾ùÓÐ18 32%µÄ·ÇIPFµÄ¼äÖÊÐԷμ²²¡»¼Õß¿ÉÄÜ»á³öÏÖ½øÐÐÐÔ·ÎÏËά»¯¡£9ÒÔÉÏËùÊöµÄ¼äÖÊÐԷμ²²¡¿É±íÏÖΪ¸÷ÖÖÁÙ´²Õï¶ÏÐÎʽ£¬°üÀ¨¹ýÃôÐÔ·ÎÑס¢½á½Ú²¡ÒÔ¼°×ÔÉíÃâÒßÐÔ¼äÖÊÐԷμ²²¡£¬ÀýÈçÀà·çʪÐԹؽÚÑ×Ïà¹ØÐÔ¼äÖÊÐԷμ²²¡¡¢ÏµÍ³ÐÔÓ²»¯²¡Ïà¹ØÐÔ¼äÖÊÐԷμ²²¡¡¢»ìºÏÐͽáµÞ×éÖ¯¼²²¡Ïà¹ØÐÔ¼äÖÊÐԷμ²²¡¡¢ÌØ·¢ÐÔ·ÇÌØÒìÐÔ¼äÖÊÐÔ·ÎÑ×ÒÔ¼°Î´·ÖÀàµÄÌØ·¢ÐÔ¼äÖÊÐÔ·ÎÑס£[8]

¶ÔÓÚÉÏÊö¼²²¡»¼ÕßÈËȺ£¬Ä¿Ç°»¹Ã»ÓлñµÃÅú×¼µÄÖÎÁÆÑ¡ÔñÄܹ»¶ÔÆä¼²²¡¹ý³Ì½øÐÐÓÐЧ¸ÉÔ¤¡£[15]×÷ΪÖÎÁÆÉϵÄÒ»¸öÄÑÌ⣬ÒÔÉÏËùÊöµÄ¼äÖÊÐԷμ²²¡Ðèͨ¹ý¶àѧ¿Æ×¨¼Ò£¨ÓÈÆäÊǺôÎü¿Æ×¨¼Ò¼°·çʪ²¡×¨¼Ò£©½øÐÐÕïÁÆ¡£[10]

Äá´ïÄá²¼

Äá´ïÄá²¼ÊÇÒ»ÖÖ°ÐÏò,×÷ÓÃÓÚÓÕ·¢·ÎÏËά»¯ÐźÅͨ·Ïà¹Ø¹Ø¼üÐÔÊÜÌåµÄС·Ö×ÓÀÒ°±ËἤøÒÖÖÆ¼Á¡£[16]Äá´ïÄá²¼ÒÑÔÚ80¸öÒÔÉϹú¼ÒÅú×¼ÓÃÓÚÌØ·¢ÐÔ·ÎÏËά»¯£¨IPF£©»¼ÕßÖÎÁÆ - ÕâÊÇÒ»ÖÖÒԷι¦ÄÜϽµÎªÌØÕ÷ÇÒ×îÖÕ¾ßÓÐÖÂËÀÐÔµÄÂýÐÔ²¡¡£Ä¿Ç°ÒѽÓÊܹýÄá´ïÄá²¼ÖÎÁƵÄÌØ·¢ÐÔ·ÎÏËά»¯»¼ÕßÈËÊýÔ¤¼ÆÒѳ¬¹ý80,000ÈË£¬²¢ÇÒÒÑÓжàÏî¹ú¼ÊÖ¸ÄÏÍÆ¼öÄá´ïÄá²¼×÷ÎªÌØ·¢ÐÔ·ÎÏËά»¯»¼ÕßµÄÖÎÁÆÓÃÒ©¡£[17]

2019Äê9Ô£¬ÃÀ¹úÅú×¼Äá´ïÄá²¼×÷ΪÊ׸öÒ²ÊÇΨһһ¸ö¿É¼õ»ºÏµÍ³ÐÔÓ²»¯²¡Ïà¹ØÐÔ¼äÖÊÐԷμ²²¡»¼Õ߷ι¦ÄÜϽµËٶȵÄÖÎÁÆÓÃÒ©¡£[18]ĿǰÒÑÏòÈ«ÇòÆäËû¹ú¼ÒµØÇøµÄ¼à¹Ü»ú¹¹Ìá½»ÁËÏà¹ØÉêÇ룬ĿǰÒÑÔÚ40¸öÒÔÉϹú¼ÒµØÇø£¨°üÀ¨Å·ÃË¡¢°ÍÎ÷¡¢¼ÓÄôóºÍÈÕ±¾£©»ñµÃÁ˼à¹ÜÅú×¼Ðí¿É¡£

Äá´ïÄá²¼Ò²Òѱ»ÃÀ¹úʳƷҩƷ¹ÜÀí¾ÖÊÚÓèÍ»ÆÆÐÔÁÆ·¨È϶¨¼°ÓÅÏÈÉóÆÀÈ϶¨£¬²¢ÇÒÖ®ºóÓÚ2020Äê3ÔÂÔÚÃÀ¹ú»ñµÃÓ¦ÓÃÓÚ¾ßÓнøÐÐÐÔ±íÐ͵ÄÂýÐÔÏËά»¯ÐÔ¼äÖÊÐԷμ²²¡µÄÖÎÁÆÐí¿É¡£[4]

ά¼ÓÌØ®£¨Äá´ïÄá²¼£©Ð¡µµ°¸

  • 2014Äê10Ô£¬»ñµÃFDAµÄÅú×¼ÓÃÓÚÖÎÁÆÌØ·¢ÐÔ·ÎÏËά»¯£¨IPF£©
  • 2015Ä꣬±»ÄÉÈë¹ú¼ÊÖ¸ÄÏ£¬²¢ÓÚ2016Äê±»ÄÉÈëÖйúIPFÕï¶ÏºÍÖÎÁÆ×¨¼Ò¹²Ê¶
  • 2017Äê9Ô£¬±»Öйú¹ú¼ÒÒ©Æ·¼à¶½¹ÜÀí¾ÖÅú×¼ÔÚÖйúÉÏÊУ¬ÓÃÓÚÖÎÁÆÌØ·¢ÐÔ·ÎÏËά»¯£¨IPF£©
  • 2018Äê1Ô£¬½øÈëÕã½­Ê¡´ó²¡Ò½±£Ä¿Â¼£¬²¢ÓÚͬÄ꿪չÁËIPF»¼ÕßÔ®ÖúÏîÄ¿
  • 2019Äê9Ô£¬ÃÀ¹úʳƷҩƷ¼à¶½¹ÜÀí¾Ö£¨FDA£©Åú׼ά¼ÓÌØ®×÷ΪÊ׸öÒ²ÊÇΨһÄܹ»¼õ»ºÏµÍ³ÐÔÓ²»¯²¡Ïà¹Ø¼äÖÊÐԷμ²²¡£¨SSc-ILD£©»¼Õ߷ι¦ÄÜϽµµÄÒ©Îï
  • 2020Äê3Ô£¬ÃÀ¹úʳƷҩƷ¼à¶½¹ÜÀí¾Ö£¨FDA£©Åú׼ά¼ÓÌØ®×÷Ϊ¾ßÓнøÐÐÐÔ±íÐ͵ÄÂýÐÔÏËά»¯ÐÔ¼äÖÊÐԷμ²²¡µÄÊ׸öÖÎÁÆÒ©Îï
  • 2020Äê4Ô£¬Å·ÖÞÒ©Æ·¼à¹Ü¾ÖÅú׼ά¼ÓÌØ®ÓÃÓÚÖÎÁÆÏµÍ³ÐÔÓ²»¯²¡Ïà¹Ø¼äÖÊÐԷμ²²¡
  • 2020Äê6Ô£¬Öйú¹ú¼ÒÒ©Æ·¼à¶½¹ÜÀí¾ÖÅú×¼ÁËά¼ÓÌØ® ϵͳÐÔÓ²»¯²¡Ïà¹Ø¼äÖÊÐԷμ²²¡µÄÊÊÓ¦Ö¢

References

[1] European Commission decision, July 13, 2020. Data on file.

[2]Flaherty KR, Wells AU, Cottin V, et al.Nintedanib in progressive fibrosing interstitial lung diseases.N Engl J Med.2019;381(18):1718-1727. doi: 10.1056/NEJMoa1908681.

[3]OFEV® positive opinion.European Medicines Agency.Available at https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-ofev-ii-27_en.pdf.Last accessed June 2020.

[4]U.S. Food and Drug Administration news release.FDA Approves First Treatment for Group of Progressive Interstitial Lung Diseases.Available athttps://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-group-progressive-interstitial-lung-diseases.Last accessed June 2020.

[5]Ofev® Product Monograph.Boehringer Ingelheim (Canada) Ltd. May 19, 2020.Available athttps://www.boehringer-ingelheim.ca/sites/ca/files/ofevpmen_4.pdf. Last accessed June 2020.

[6]Nippon Boehringer Ingelheim Co., Ltd. press release.Available athttps://www.boehringer-ingelheim.jp/press-release/20200529_01. Last accessed June 2020.

[7]British Lung Foundation.What is pulmonary fibrosis? Available athttps://www.blf.org.uk/support-for-you/pulmonary-fibrosis/what-is-pulmonary-fibrosis. Last accessed June 2020.

[8]Cottin V, Hirani NA, Hotchkin DL, et al.Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases. Eur Respir Rev 2018;27(150):pii:180076.

[9]Wijsenbeek M, Kreuter M, Fischer A, et al.Non-IPF progressive fibrosing interstitial lung disease (PF-ILD): the patient journey.Am J Respir Crit Care Med 2018;197:A1678.

[10]Kolb M, Vaa¨¢kov¨¢ M. The natural history of progressive fibrosing interstitial lung diseases.Respiratory Research 2019:20:57.

[11]Richeldi L, du Bois RM, Raghu G, et al; INPULSIS® Trial Investigators.Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis.N Engl J Med.2014;370(22):2071-2082.

[12]Richeldi L, Costabel U, Selman M, et al.Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis.N Engl J Med.2011;365(12):1079-1087.

[13]Distler O, Highland KB, Gahlemann M, et al; the SENSCIS Trial Investigators.Nintedanib for systemic sclerosis-associated lung disease.N Engl J Med.2019;380(26):2518-2528. doi:10.1056/NEJMoa1903076.

[14]Swigris JJ, Richeldi L, Wijsenbeek M, et al.Effects of Nintedanib on Dyspnea, Cough and Quality of Life in Patients with Progressive Fibrosing Interstitial Lung Diseases: Findings from the INBUILD trial.ID number: 9455.

[15]Flaherty KR, Brown KK, Wells AU, et al.Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease.BMJ Open Resp Res 2017;4:e000212. doi:10.1136/bmjresp-2017-000212.

[16] European Summary of Product Characteristics Ofev®, July 13, 2020. Data on file.

[17]Raghu G, et al.An Official ATS/ERS/JRS/ALAT Clinical Practice Guidelines: Treatment of Idiopathic Pulmonary Fibrosis: Executive Summary.Am J Respir Crit Care Med.2015; 192(2)238  248.

[18]U.S. Food and Drug Administration news release.FDA approves first treatment for patients with rare type of lung disease.Available at https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-patients-rare-type-lung-disease.Last accessed June 2020.

Ïà¹ØÈÈ´ÊËÑË÷£º
¹ØÓÚÎÒÃÇ ÁªÏµÎÒÃÇ ÈËÔ±²éѯ ÃâÔðÉùÃ÷ ÓÑÇéÁ´½Ó ¹óÖÝÍøLOGO ¹ã¸æ¿¯Àý ±¾Õ¾ÓòÃû °Ù¶ÈÐÂÎÅ